Suicide in schizophrenia, clozapine, and adoption of evidence-based medicine

Journal of Clinical Psychiatry

Volumn 66, Issue 4, 2005, Pages 530-533

  Meltzer, Herbert Y ^a  

^a VANDERBILT UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CLOZAPINE; LITHIUM; LITHIUM CARBONATE; OLANZAPINE; RISPERIDONE;

AGRANULOCYTOSIS; CLINICAL TRIAL; DRUG EFFICACY; DRUG FORMULATION; DRUG INDICATION; DRUG SAFETY; DRUG TOLERABILITY; EVIDENCE BASED MEDICINE; HUMAN; HYPERSALIVATION; HYPOTENSION; METABOLIC DISORDER; MORTALITY; NOTE; PRIORITY JOURNAL; RISK ASSESSMENT; RISK BENEFIT ANALYSIS; SCHIZOPHRENIA; SEIZURE; SIDE EFFECT; SUICIDAL BEHAVIOR;

EID: 17844369155     PISSN: 01606689     EISSN: None     Source Type: Journal    
DOI: 10.4088/jcp.v66n0417     Document Type: Note

References (30)

1. Emsley R, Oosthuizen P. Evidence-based pharmacotherapy of schizophrenia. Int J Neuropsychopharmacol 2004;7:219-238
2. Shumway M, Sentell TL. An examination of leading mental health Journals for evidence to inform evidence-based practice. Psychiatr Serv 2004;55:649-653
3. Essock SM. Editor's introduction: antipsychotic prescribing practices. Schizophr Bull 2002;28:1-4
4. Hamann J, Langer B, Leucht S, et al. Medical decision making in antipsychotic drug choice for schizophrenia. Am J Psychiatry 2004;161: 1301-1304
5. Meltzer HY, Okayli G. Reduction of suicidality during clozapine treatment of neuroleptic-resistant schizophrenia: impact on risk-benefit assessment. Am J Psychiatry 1995;152:183-190
6. Meltzer HY. Treatment of suicidality in schizophrenia. Ann N Y Acad Sci 2001;932:44-58
7. Modestin J, Dal Pian D, Agarwalla P. Clozapine diminishes suicidal behavior: a retrospective evaluation of clincial records. J Clin Psychiatry 2005;66:534-538
8. Nordentoft M, Jeppesen P, Abel M, et al. OPUS study, suicidal behaviour, suicidal ideation and hopelessness among patients with first-episode psychosis: one-year follow-up of a randomised controlled trial. Br J Psychiatry Suppl 2000;43:s98-s106
9. Kallert TW, Leisse M, Winiecki P. Suicidality of chronic schizophrenic patients in long-term community care. Crisis 2004;25:54-64
10. Meltzer HY, Alphs L, Green AI, et al, for the International Suicide Prevention Trial Study Group. Clozapine treatment for suicidality in schizophrenia: International Suicide Prevention Trial (InterSePT). Arch Gen Psychiatry 2003;60:82-91
11. American Psychiatric Association. Practice Guideline for the Assessment and Treatment of Patients With Suicidal Behaviors. Am J Psychiatry 2003; 160(suppl 11):1-60
12. Meltzer HY, Lee MA, Ranjan R, et al. Relapse following clozapine withdrawal: effect of cyproheptadine plus neuroleptic. Psychopharmacology (Berl) 1996;124:176-187
13. Hennen J, Baldessarini RJ. Suicidal risk during treatment with clozapine: a meta-analysis. Schizophr Res 2005;73:139-145
14. Sernyak MJ, Desai R, Stolar M, et al. Impact of clozapine on completed suicide. Am J Psychiatry 2001;158:931-937
15. Miller AL, Hall CS, Buchanan RW, et al. The Texas Medication Algorithm Project antipsychotic algorithm for schizophrenia: 2003 update. J Clin Psychiatry 2004;65:500-508
16. International Psychopharmacology Algorithm Project. Available at: http://www.IPAP.org. Accessed October 15, 2004
17. Sharma V. Atypical antipsychotics and suicide in mood and anxiety disorders. Bipolar Disord 2003;5(suppl 2):48-52
18. Ernst CL, Goldberg JF. Antisuicide properties of psychotropic drugs: a critical review. Harv Rev Psychiatry 2004;12:14-41
19. Angst A, Angst F, Gerber-Werder R, et al. Suicide in 406 mood-disorder patients with and without long-term medication: a 40 to 44 years' follow-up. Arch Suicide Res. In press
20. Tondo L, Hennen J, Baldessarini RJ. Lower suicide risk with long-term lithium treatment in major affective illness: a meta-analysis. Acta Psychiatr Scand 2001;104:163-172
21. Khan A, Khan SR, Leventhal RM, et al. Symptom reduction and suicide risk among patients treated with placebo in antipsychotic clinical trials: an analysis of the Food and Drug Administration database. Am J Psychiatry 2001;158:1449-1454
22. Barak Y, Mirecki I, Knobler HY, et al. Suicidality and second generation antipsychotics in schizophrenia patients: a case-controlled retrospective study during a 5-year period. Psychopharmacology (Berl) 2004;175: 215-219
23. Meltzer HY. Clozapine and suicide [letter]. Am J Psychiatry 2002;159: 322
24. Ertugrul A. Clozapine and suicide [letter]. Am J Psychiatry 2002;159:323
25. Pompili M, Girardi P, Ruberto A, et al. Toward a new prevention of suicide in schizophrenia. World J Biol Psychiatry 2004;5:201-210
26. Gerson SL. Clozapine: deciphering the risks [editorial]. N Engl J Med 1993;329:204-205
27. Honigfeld G, Arellano F, Sethi J, et al. Reducing clozapine-related morbidity and mortality: five years of experience with the Clozaril National Registry. J Clin Psychiatry 1998;59(suppl 3):3-7
28. Hall RL, Smith AG, Edwards JG. Haematological safety of antipsychotic drugs. Expert Opin Drug Saf 2003;2:395-399
29. Zhang M, Owen RR, Pope SK, et al. Cost-effectiveness of clozapine monitoring after the first 6 months. Arch Gen Psychiatry 1996;53: 954-958
30. Gerson SL, Meltzer H. Mechanisms of clozapine-induced agranulocytosis. Drug Saf 1992;7(suppl 1):17-25